Sengsayadeth S, Malard F, Savani B N, Garderet L, Mohty M
Section of Hematology and Stem Cell Transplant, Vanderbilt Ingram Cancer Center, Nashville, TN, USA.
Department of Haematology, Saint Antoine Hospital, University Pierre and Marie Curie, and INSERM UMRs 938, Paris, France.
Blood Cancer J. 2017 Mar 24;7(3):e545. doi: 10.1038/bcj.2017.23.
Transplant-eligible patients with multiple myeloma (MM) now have extended survival after diagnosis owing to effective modern treatment strategies that include new agents in induction therapy, autologous stem cell transplant (ASCT), consolidation therapy and posttransplant maintenance therapy. Standard of care for newly diagnosed, fit patients includes ASCT and, often nowadays, posttransplant maintenance. Several large studies have shown the efficacy of maintenance with thalidomide, lenalidomide and bortezomib in the treatment scheme of MM with regards to prolonging progression-free survival and, to a lesser degree, overall survival. Herein we discuss the data currently available to support the use of maintenance therapy in patients after ASCT as well as the newer available agents that may be a part of its changing landscape in the years to come.
由于有效的现代治疗策略，包括诱导治疗中使用新药物、自体干细胞移植（ASCT）、巩固治疗和移植后维持治疗，符合移植条件的多发性骨髓瘤（MM）患者在诊断后的生存期得以延长。新诊断的健康患者的标准治疗包括ASCT，如今还常常包括移植后维持治疗。多项大型研究表明，在MM治疗方案中使用沙利度胺、来那度胺和硼替佐米进行维持治疗，在延长无进展生存期方面有效，在一定程度上也能延长总生存期。在此，我们讨论目前可支持在ASCT后患者中使用维持治疗的数据，以及未来几年可能成为其不断变化格局一部分的新型可用药物。
